8 completed, 2 recruiting, 2 terminated, 1 unknown. 13 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Recruiting 2, Terminated 2, Unknown 1 |
| Phase 3 | 3 | Recruiting 2, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Cryptococcosis: new trials by email Literature Review of Cryptococcosis trials Research Report on Cryptococcosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Trial For Cryptococcal Meningitis (PLATFORM-CM) Standard of care, Oteseconazole - antifungal therapy 1, Turletricin injection - antifungal therapy 2 - Hiv, Cryptococcal Meningitis | Phase 2 / Phase 3 | Recruiting | David Boulware | 2000 | 2025-05-28 | 2026-07-27 |
| Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis AMBITION trial control, Flucytosine - Cryptococcal Meningitis | Phase 2 | Completed | University of Minnesota | 48 | 2024-04-09 | 2025-08-27 |
| Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) MAT2203, Amphotericin B - Cryptococcal Meningitis | Phase 1 / Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 178 | 2019-10-24 | 2023-03-31 |
| Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia Single dose liposomal Amphotericin and Fluconazole, Fluconazole - Cryptococcal Meningitis | Phase 2 / Phase 3 | Recruiting | Makerere University | 356 | 2019-06-20 | 2026-04-28 |
| Treatment With Tamoxifen in Cryptococcal Meningitis Tamoxifen, Amphotericin B, Fluconazole - Meningitis Streptococcal, Hiv | Phase 2 | Completed | Oxford University Clinical Research Unit, Vietnam | 50 | 2017-10-10 | 2019-12-02 |
| Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Fluconazole, Flucytosine, lumbar punctures - Cryptococcal Meningitis, HIV | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 41 | 2012-05-01 | 2016-07-12 |
| High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Fluconazole, Amphotericin B - Cryptococcal Meningitis, HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 168 | 2010-04-16 | 2021-11-04 |
| Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Mycograb, placebo - Cryptococcal Meningitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 3 | 2007-03-01 | 2008-12-12 |
| Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Efungumab (Mycograb), placebo, Amphotericin B - Cryptococcal Meningitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 38 | 2006-08-01 | 2009-02-19 |
| Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis Amphotericin B, Fluconazole - Cryptococcal Meningitis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 143 | 2005-05-01 | 2012-05-16 |
| PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893) Posaconazole oral suspension - Mycoses | Phase 2 | Completed | Merck Sharp & Dohme LLC | 98 | 2001-01-01 | 2015-12-31 |
| Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis Itraconazole, Flucytosine, Fluconazole - Meningitis, Cryptococcal, HIV Infections | Phase 2 | Completed | InterMune | 60 | 2000-01-01 | 2009-06-03 |
| Dexamethasone in Cryptococcal Meningitis Flucytosine, Fluconazole, Amphotericin B - Meningitis, Cryptococcal, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2021-10-28 |
Meningitis, Cryptococcal (12) · HIV Infections (5) · Acquired Immunodeficiency Syndrome (3) · Meningitis (3) · AIDS-Related Opportunistic Infections (1) · Aspergillosis (1) · Bacterial Infections (1) · Brain Diseases (1) · Candidiasis (1) · Invasive Fungal Infections (1) · Meningoencephalitis (1) · Mucormycosis (1) · Mycoses (1)
Bacterial Infections and Mycoses (13) · Infections (13) · Central Nervous System Diseases (12) · Central Nervous System Fungal Infections (12) · Central Nervous System Infections (12) · Meningitis, Fungal (12) · Mycoses (12) · Nervous System Diseases (12) · Neuroinflammatory Diseases (12) · Meningitis (9) · Blood-Borne Infections (7) · Communicable Diseases (7) · Genital Diseases (7) · Immune System Diseases (7)
Amphotericin B (8) · Fluconazole (7) · Flucytosine (5) · efungumab (2) · liposomal amphotericin B (2) · Dexamethasone (1) · Itraconazole (1) · Spinal Puncture (1) · Standard of Care (1) · Tamoxifen (1) · amphotericin B, deoxycholate drug combination (1) · interferon gamma-1b (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Novartis Pharmaceuticals (2) · ANRS, Emerging Infectious Diseases (1) · David Boulware (1) · InterMune (1) · Makerere University (1) · Matinas BioPharma Nanotechnologies, Inc. (1) · Merck Sharp & Dohme LLC (1) · Oxford University Clinical Research Unit, Vietnam (1) · University of Minnesota (1)
Uganda (5) · United States (5) · Peru (2) · South Africa (2) · Thailand (2) · Burundi (1) · Côte d’Ivoire (1) · India (1) · Kenya (1) · Puerto Rico (1) · Vietnam (1) · Zimbabwe (1)
David B Meya (1) · David B Meya, MBChB, MMed, PhD (1) · David R Boulware (1) · David R Boulware, MD, MPH (1) · J Jacobson (1) · Jeremy Day, MD (1) · Olivier Bouchaud, PhD (1) · Robert A. Larsen, MD (1) · Umesh G. Lalloo, MD, FRCP (1)
PMID 16436724, PMID 19441980, PMID 19897055, PMID 30801037, PMID 32747357, PMID 34581270, PMID 36780493, PMID 37606364, PMID 38943665, PMID 39044381, PMID 39972326, PMID 40665233, PMID 40795226